Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology
Por um escritor misterioso
Descrição
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label
Statin Use Associated with Lower Incidence of Developing Thyroid
Statin use associated with lower incidence of developing thyroid
Proposal for Standardization of Primary and Secondary Outcomes in
Teprotumumab for patients with active thyroid eye disease: a
Rosuvastatin in the Primary Prevention of Cardiovascular Disease
Management of thyroid eye disease: a Consensus Statement by the
Management of Thyroid Eye Disease: A Consensus Statement by the
Proposal for Standardization of Primary and Secondary Outcomes in
Effect of dapagliflozin on the rate of decline in kidney function
Graves Disease: Practice Essentials, Pathophysiology, Epidemiology
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label
Graves Disease: Practice Essentials, Pathophysiology, Epidemiology
Management of Thyroid Eye Disease: A Consensus Statement by the
de
por adulto (o preço varia de acordo com o tamanho do grupo)
